MediWound Ltd. (MDWD)

NASDAQ: MDWD · IEX Real-Time Price · USD
1.86
+0.07 (3.91%)
Jul 5, 2022 3:59 PM EDT - Market closed

Company Description

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration.

It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.

MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.
MediWound Logo
Country Israel
Founded 2000
IPO Date Mar 20, 2014
Industry Pharmaceuticals
Sector Health Care
Employees 77
CEO Sharon Malka

Contact Details

Address:
42 Hayarkon Street
Yavne 8122745
Israel
Phone 972 7 797 14100
Website mediwound.com

Stock Details

Ticker Symbol MDWD
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 0001593984
CUSIP Number M68830104
ISIN Number IL0011316309
SIC Code 2833

Key Executives

Name Position
Prof. Lior Rosenberg M.D. Co-Founder and Chief Medical Technology Officer
Boaz Gur-Lavie CPA, M.B.A. Chief Financial Officer
Yaron Meyer Adv. Executive Vice President, General Counsel and Corporate Secretary
Dr. Ety Klinger Chief Research & Development Officer
Stephen T. Wills CPA, CPA, MST Executive Chairman
Ofer Gonen B.Sc. Chief Executive Officer and Director

Latest SEC Filings

Date Type Title
Jun 9, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Jun 6, 2022 EFFECT Notice of Effectiveness
May 25, 2022 F-3 Registration statement by foreign private issuers
May 17, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 17, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
May 12, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Mar 22, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
Mar 17, 2022 SC 13D General statement of acquisition of beneficial ownership
Mar 17, 2022 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
Mar 17, 2022 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]